These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 8524802)

  • 1. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
    Suzich JA; Ghim SJ; Palmer-Hill FJ; White WI; Tamura JK; Bell JA; Newsome JA; Jenson AB; Schlegel R
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11553-7. PubMed ID: 8524802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.
    Moore RA; Santos EB; Nicholls PK; White KL; Anderson DM; Lloyd A; Topley P; Romanos M; Thomsen L; Parmar V; Walcott S; Gough GW; Stanley MA
    Virology; 2002 Dec; 304(2):451-9. PubMed ID: 12504584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.
    Ghim S; Newsome J; Bell J; Sundberg JP; Schlegel R; Jenson AB
    Exp Mol Pathol; 2000 Jun; 68(3):147-51. PubMed ID: 10816383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection.
    Nicholls PK; Klaunberg BA; Moore RA; Santos EB; Parry NR; Gough GW; Stanley MA
    Virology; 1999 Dec; 265(2):365-74. PubMed ID: 10600607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
    Yuan H; Estes PA; Chen Y; Newsome J; Olcese VA; Garcea RL; Schlegel R
    J Virol; 2001 Sep; 75(17):7848-53. PubMed ID: 11483728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.
    Kirnbauer R; Chandrachud LM; O'Neil BW; Wagner ER; Grindlay GJ; Armstrong A; McGarvie GM; Schiller JT; Lowy DR; Campo MS
    Virology; 1996 May; 219(1):37-44. PubMed ID: 8623552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.
    Stanley MA; Moore RA; Nicholls PK; Santos EB; Thomsen L; Parry N; Walcott S; Gough G
    Vaccine; 2001 Apr; 19(20-22):2783-92. PubMed ID: 11282188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
    Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
    Johnston KB; Monteiro JM; Schultz LD; Chen L; Wang F; Ausensi VA; Dell EC; Santos EB; Moore RA; Palker TJ; Stanley MA; Jansen KU
    Virology; 2005 Jun; 336(2):208-18. PubMed ID: 15892962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes.
    Chen Y; Ghim SJ; Jenson AB; Schlegel R
    J Gen Virol; 1998 Sep; 79 ( Pt 9)():2137-46. PubMed ID: 9747722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes.
    Nicholls PK; Moore PF; Anderson DM; Moore RA; Parry NR; Gough GW; Stanley MA
    Virology; 2001 Apr; 283(1):31-9. PubMed ID: 11312659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model.
    Bell JA; Sundberg JP; Ghim SJ; Newsome J; Jenson AB; Schlegel R
    Pathobiology; 1994; 62(4):194-8. PubMed ID: 7734063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
    Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
    Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic immunisation with COPV early genes by epithelial DNA delivery.
    Moore RA; Walcott S; White KL; Anderson DM; Jain S; Lloyd A; Topley P; Thomsen L; Gough GW; Stanley MA
    Virology; 2003 Sep; 314(2):630-5. PubMed ID: 14554090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-mediated immune responses to COPV early proteins.
    Jain S; Moore RA; Anderson DM; Gough GW; Stanley MA
    Virology; 2006 Dec 5-20; 356(1-2):23-34. PubMed ID: 16949120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
    Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
    Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against papillomavirus with a polynucleotide vaccine.
    Donnelly JJ; Martinez D; Jansen KU; Ellis RW; Montgomery DL; Liu MA
    J Infect Dis; 1996 Feb; 173(2):314-20. PubMed ID: 8568291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination.
    Hines JF; Ghim SJ; Christensen ND; Kreider JW; Barnes WA; Schlegel R; Jenson AB
    Gynecol Oncol; 1994 Oct; 55(1):13-20. PubMed ID: 7525426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.
    Lin YL; Borenstein LA; Ahmed R; Wettstein FO
    J Virol; 1993 Jul; 67(7):4154-62. PubMed ID: 7685411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
    Park JS; Oh YK; Kang MJ; Kim CK
    J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.